Top Story Today
GSK Drops $10.6 Billion on Two Drugs Nobody Can Buy Yet
GSK is acquiring Nuvalent for $10.6 billion in all cash, paying a 40% premium for two late-stage lung cancer drugs that haven't been approved by the FDA. It's the company's largest deal in over a decade, driven by a looming patent cliff on its blockbuster HIV drug dolutegravir. One drug already has an FDA decision date in September; the other is going head-to-head against Roche's standard of care. Shares dropped 3% on the news, and analysts say the deal "allows little margin for error."
Why it matters: This is one of the largest biopharma M&A deals of 2026 and signals GSK's aggressive pivot toward precision oncology, reshaping the competitive landscape against Roche and Pfizer in targeted lung cancer treatments.
Read more →Clinical Breakthroughs
A Drug Left for Dead Just Nailed Phase 3 for the First Weekly HIV Pill
Merck and Gilead's once-weekly oral HIV pill hit its primary endpoints in two Phase 3 trials, matching daily Biktarvy at keeping the virus suppressed. The twist: islatravir was shelved in 2021 after it started destroying the immune cells HIV targets. A lower dose and a new partner (Gilead's lenacapavir) brought it back to life. Regulatory filings are underway.
Read more →92% of Pancreatic Cancer Patients Responded. Read That Again.
Tango Therapeutics reported that 11 of 12 pancreatic cancer patients responded to its two-drug combo, sending shares up 53% in a single day. Second-line treatments for this cancer barely crack 15%. The dataset is tiny, but the signal is loud enough that Tango is racing toward Phase 3.
Read more →Inhaled Insulin Flopped With Adults. Turns Out Kids Were the Real Market.
MannKind's Afrezza just became the first needle-free inhaled insulin approved for children six and older. About 27% of kids with type 1 diabetes have significant needle anxiety, and that fear leads to skipped doses and worse outcomes. The drug showed comparable blood sugar control to injections with no lung function concerns.
Read more →Deals and M&A
J&J Paid $1 Billion for a Cancer Drug That's Never Been Tested in Humans
Johnson & Johnson is acquiring Firefly Bio for $1 billion, all upfront, for a preclinical platform called degrader antibody conjugates (DACs). The technology combines antibody targeting with protein degradation to go after KRAS-driven cancers, including pancreatic. It's J&J's latest oncology acquisition as the company continues to build out its cancer pipeline.
Read more →AstraZeneca's GLP-1 Pill Posts Real Data. The Obesity Race Just Got a Third Lane.
AstraZeneca's oral GLP-1 pill, elecoglipron, delivered 10.5% weight loss at 26 weeks in Phase 2b. That trails Eli Lilly's numbers, but analysts call it "good enough to compete" in a market projected to exceed $100 billion. Phase 3 trials start later this year.
Read more →Regulatory and Financings
The First Pill to Cross the Brain's Toughest Barrier Gets Fast-Tracked
Sanofi's venglustat scored FDA Priority Review for Gaucher disease type 3, with a decision date of November 25. If approved, it would be the first therapy to cross the blood-brain barrier and treat the neurological devastation of this ultra-rare disease. Phase 3 data showed significant improvement over enzyme replacement therapy (p = 0.007).
Read more →An $800 Million Startup Wants Another Half Billion From Wall Street
Parabilis Medicines is targeting a roughly $450 million Nasdaq IPO at $17 to $19 per share, backed by a Regeneron partnership worth up to $2.3 billion. The deal is shaping up as the biggest test of whether biotech's IPO window is genuinely reopening in 2026.
Read more →Pfizer's Weekly Shot Opens the Door for Kids With Hemophilia
HYMPAVZI just won an expanded FDA label covering children as young as six with hemophilia A or B, including those with inhibitors. In the Phase 3 BASIS trial in adolescents and adults, treated bleeds dropped from roughly 20 per year to 1.4: a 93% reduction. For hemophilia B inhibitor patients, HYMPAVZI is the first anti-TFPI agent and first once-weekly subcutaneous prophylaxis option approved.
Read more →